Monitoring the frequency of side effects of drugs

EDITOR,-R Bracchi highlights the need for general practitioners to have more information on the frequency of adverse drug events. 1 Premarketing trials, which are limited by their small size, short duration, narrow set of indications, and exclusion criteria, provide some data but may not accurately...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 1996-06, Vol.312 (7043), p.1418-1419
Main Authors: Martin, Richard, Hilton, Sean, Richards, Nicky, George, David A. B. S. T.
Format: Article
Language:English
Subjects:
Business structures
Clinical medicine
Dosage
Drug effects
Drug prescriptions
General practice
Letters
Pharmaceutical preparations
Prescription drugs
Side effects
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:EDITOR,-R Bracchi highlights the need for general practitioners to have more information on the frequency of adverse drug events. 1 Premarketing trials, which are limited by their small size, short duration, narrow set of indications, and exclusion criteria, provide some data but may not accurately reflect clinical practice. 2 Spontaneous reporting after marketing (the yellow card scheme) is an essential early warning system, but many adverse drug events remain unreported, one of the reasons being lack of confidence in diagnosing an adverse reaction. 3 We describe here an alternative source of information on adverse drug events experienced in general practice.
ISSN:0959-8138
1468-5833
1756-1833
DOI:10.1136/bmj.312.7043.1418c